Last reviewed · How we verify
Human platelets
At a glance
| Generic name | Human platelets |
|---|---|
| Sponsor | Cellphire Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- pAF for the Treatment of Osteoarthritis (PHASE1, PHASE2)
- The Body's Affect on Vitamin C (PHASE1)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction (PHASE2)
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
- Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis (NA)
- rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
- A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human platelets CI brief — competitive landscape report
- Human platelets updates RSS · CI watch RSS
- Cellphire Therapeutics, Inc. portfolio CI